<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213885</url>
  </required_header>
  <id_info>
    <org_study_id>PXL330-001</org_study_id>
    <nct_id>NCT04213885</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position</brief_title>
  <official_title>Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking With Corneal Thinning Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Specialists of Indiana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye Specialists of Indiana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the Peschke PXL-330 is safe and effective in the treatment of corneal
      thinning conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, infectious keratitis,
      or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on
      corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy
      delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal
      topography, visual acuity, intraocular pressure and visual function questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2029</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Treatment of patients with disease</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Randomized at outset</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean keratometry in diopters</measure>
    <time_frame>1 year</time_frame>
    <description>Average keratometry across the anterior topography of the cornea computed by a validated Scheimpflug topographer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of best corrected visual acuity on the validated early-treatment diabetic retinopathy study scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Keratoconus, Unstable</condition>
  <condition>Ectasia Corneal</condition>
  <condition>Bacterial Keratitis</condition>
  <arm_group>
    <arm_group_label>Pulsed Accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mW, 5 sec, 5 sec off, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9mW continuous, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PXL 330 Platinum device/Riboflavin</intervention_name>
    <description>30mW, 5 sec, 5 sec off, 10 minutes of illumination</description>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_label>Pulsed Accelerated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Criterion 1,2,3 are required for all participants. Participants must
        also meet one or more of criteria 4-12. Criteria 13 is only relevant for contact lens
        wearers.

          1. 12 years of age or older

          2. Signed written informed consent

          3. Willingness and ability to comply with schedule for follow-up visits

          4. Presence of central or inferior steepening

          5. Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid
             marginal degeneration

          6. Presence of one or more findings associated with keratoconus or pellucid marginal
             degeneration, such as

               1. Fleisher ring

               2. Vogt's striae

               3. Decentered corneal apex

               4. Munson's sign

               5. Rizzutti's sign

               6. Apical corneal scarring consistent with Bowman's breaks

               7. Scissoring of the retinoscopic reflex

               8. Crab-claw appearance on topography

          7. Steepest keratometry (Kmax) value greater than or equal to 47.2

          8. I-S keratometry difference &lt; 1.5 D on the Pentacam map or topography map

          9. Posterior corneal elevation &gt; 16 microns

         10. Thinnest corneal point &lt;485 microns

         11. Predicted Post LASIK/PRK stromal ablation depth &lt;350 microns or expected keratometry
             &gt;47.2, or patients undergoing PRK/SMILE in keratoconus suspect eyes

         12. Bacterial or fungal keratitis persistent and not responding despite &gt; 2 weeks of
             standard antimicrobial therapy or with rapid progression of corneal thinning, with
             loss of &gt;25% corneal thickness

         13. Contact lens wearers only:

               1. Removal of contact lenses for the require period of time prior to the screening
                  refraction:

        Contact Lens Type Discontinuations Time: Soft, 1 week; Soft Extended Wear, 2 weeks; Soft
        Toric, 3 weeks; Rigid Gas Permeable, 2 weeks per decade of wear -

        Exclusion Criteria:

          1. Eyes classified as normal or atypical normal on the severity grading scheme

          2. Corneal pachymetry at the screening exam that is &lt;300 microns at the the thinnest
             point in the eye(s) to be treated.

          3. Previous ocular condition (other than refractive error) in the eye(s) to be treated
             that may predispose the eye for future complications, for example:

               1. History of or active corneal disease (e.g. herpes simplex, herpes zoster
                  keratitis, recurrent erosion syndrome, acanthamoeba, etc.)

               2. Clinically significant corneal scarring the CXL treatment zone that is not
                  related to keratoconus or, in the investigator's opinion, will interfere with the
                  cross-linking procedure.

          4. Pregnancy (including plan to become pregnant) or lactation during the course of the
             study

          5. A known sensitivity to the study medications

          6. Patients with nystagmus or any other condition that would prevent a steady gaze during
             the CXL treatment of diagnostic tests.

          7. Patients with a current condition that, in the physician's opinion, wold interfere
             with or prolong epithelial healing.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clark L Springs, MD</last_name>
    <phone>317-925-2200</phone>
    <email>csprings@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Glenn Kirk, OD</last_name>
    <phone>317-925-2200</phone>
    <email>gkirk@esicare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye Specialists of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clark L Springs, MD</last_name>
      <phone>317-925-2200</phone>
      <email>csprings@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Glenn Kirk, OD</last_name>
      <phone>317-925-2200</phone>
      <email>gkirk@esicare.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

